CONAGEN EXPANDS INNOVATIVE NUTRITIONAL PRODUCTS PORTFOLIO WITH DEVELOPMENT OF HIGH-PURITY SULFORAPHANE

KUALA LUMPUR, Nov 30 (Bernama) -- Conagen has announced the development of its 99 per cent high-purity sulforaphane, expanding on its portfolio of innovative nutritional products through biotechnology.

Made by a proprietary bioconversion technology, the company plans to begin the commercialisation path in 2023, according to a statement.

Conagen’s bioconversion methods enable the production of sustainable products from many naturally occurring compounds regardless of rarity or small quantities occurring in nature.

“As a supplement product, Conagen’s high-purity sulforaphane is appealing to consumers as the levels found in raw vegetables are too low to realise many of its promising health benefits.

“Through Conagen’s bioconversion technology, we’re uncovering the great potential in sulforaphane as a powerful active health ingredient for consumers who are personalising nutrition to support health functions,” said senior vice-president of innovation, Casey Lippmeier, Ph.D.

Found in cruciferous vegetables including arugula, bok choy, and broccoli, sulforaphane has been associated with supporting health benefits against cancer, diabetes, digestion, and heart disease and promoting cognition.

With biotechnology and biomanufacturing advancements, much like Conagen’s bioconversion technology, more nutritional offerings are produced at a high-quality and global scale.

Conagen’s sulforaphane is ideal for non-GMO supplement solutions to formulate products with a sustainable and natural consumer appeal. More research is emerging for understanding the optimistic effects on multiple health functions.

-- BERNAMA